AbCellera Biologics Inc.
ABCL
Rank in Stocks
#4176
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Share Price
$11.85
Last synced: 2026-10-16
Market Cap
$3.84B
Change (1 day)
-6.59%
Change (1 year)
111.90%
Country
CA
Trade AbCellera Biologics Inc. (ABCL)
Category
Healthcare
EPS for AbCellera Biologics Inc. (ABCL)
EPS as of June 2026 TTM: $-0.54
According to AbCellera Biologics Inc. latest financial reports and stock price the company's current EPS (TTM) is $-0.54. At the end of 2023 the company had a EPS of $-0.51 a decrease compared to its 2022 EPS that were of $0.56.
EPS history for AbCellera Biologics Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.54 | -1.82% |
| 2024 | $-0.55 | 7.84% |
| 2023 | $-0.51 | -191.07% |
| 2022 | $0.56 | 0.00% |
| 2021 | $0.56 | 75.00% |
| 2020 | $0.32 | -3,206.80% |
| 2019 | $-0.01 | -615.00% |
| 2018 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -3,307.41% |
US
|
|
| $-7.98 | 1,377.78% |
US
|
|
| $-5.29 | 879.63% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -5,237.04% |
NL
|
